Perioperative and Conventionally Timed Chemotherapy in Operable Breast Cancer
Adjuvant chemotherapy with CMF in pathological stage II breast cancer has been shown by the Milan Group to produce a disease-free survival and overall survival advantage at 6 years in premenopausal patients (Bonadonna et al. 1978). The value of adjuvant chemotherapy in postmenopausal patients is less well established, although it seems likely to be real. It has been suggested that treatment success may well be dose related in all patients (Bonadonna and Valagussa 1981) and toxicity related (Carpenter et al. 1982). The role of adjuvant chemotherapy in node-negative patients has still to be confirmed (Senn et al. 1981).
KeywordsToxicity Oncol Bacillus Methotrexate Folate
Unable to display preview. Download preview PDF.
- Bonadonna G, Rossi A, Tancini G, Brambilla C, Marchini S, Valagussa P, Veronesi U (1981) Adjuvant treatment for breast cancer. The Milan Institute experience. Proceed was of the 3rd international conference on the adjuvant therapy of cancer. March 18–21, TucsonGoogle Scholar
- Jungi WF, Brunner KW, Cavalli F, Martz G, Rosset G, Barrelet L (1981) Short or long term adjuvant chemotherapy for breast cancer. Proc Am Soc Clin Oncol 22:435 (Abstract C399)Google Scholar
- Senn HJ, Jungi WF, Amgwerd R (1981) Chemoimmunotherapy with LMF plus BCG in node-positive and node-positive breast cancer. In: Adjuvant therapy for cancer III. Salmon SE, Jones SE (eds). Grune and Stratton, New York, 385–390Google Scholar